Sep 30,2024

Blood Sensor Market Is Expected To Reach Revenue Of USD 28.4 Bn By 2033, At 9.4% CAGR

The global blood sensor market is projected to grow from USD 12.6 billion in 2024 to USD 28.4 billion by 2033, achieving a CAGR of 9.4%. The market's growth is driven by the increasing prevalence of chronic diseases, such as diabetes and cardiovascular disorders, and the rising adoption of non-invasive monitoring devices like smartwatches and fitness bands. Wearable blood sensors are expected to dominate the market, particularly blood glucose sensors, which will account for 35.1% of the market share in 2024. Key trends include the integration of AI and machine learning to enhance sensor functionality and a shift towards non-invasive monitoring, which alleviates patient discomfort.

View Analyst & Ambassador Comments
Go to original news
Jun 24,2024

embecta-sponsored Abstracts Presented at American Diabetes Association’s 84th Scientific Sessions Highlight Unmet Need for Patch Pumps with 300u Insulin Reservoir

Embecta Corp., a global leader in diabetes care, presented research at the American Diabetes Association’s 84th Scientific Sessions highlighting the benefits of a patch pump with a larger 300-unit insulin reservoir for adults with type 2 diabetes (T2D). The studies showed that the 300-unit reservoir could significantly reduce the number of patch pump changes needed, compared to a 200-unit reservoir, potentially allowing for longer wear times and greater convenience. This solution addresses the unmet need for better insulin delivery options in the T2D population. Embecta has submitted a 300-unit patch pump system to the FDA for approval.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 28,2024

Terumo Cardiovascular Announces 510(K) Clearance For The CDI OneView™ Monitoring System All-new modular, expandable design displays up to 22 vital patient parameters with real-time convenienc...

Terumo Cardiovascular, a global leader in cardiovascular surgery technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the CDI OneView Monitoring System. The next-generation CDI Systems platform provides visibility of key patient parameters during cardiopulmonary bypass surgery, critical to perfusion safety and improving patient outcomes.

REGULATORY FDA
View Analyst & Ambassador Comments
Go to original news
Sep 27,2024

New clinical data demonstrate excellent lesion durability with PulseSelect™ Pulsed Field Ablation System in real-world setting as approvals and adoption expand globally

Medtronic announced clinical results for its PulseSelect™ Pulsed Field Ablation (PFA) System, demonstrating a high rate of durable lesion formation for treating atrial fibrillation (AFib). The study showed 98% durable isolation in pulmonary veins and successful vein isolation in 96% of patients after two months. These findings support PulseSelect's effectiveness in AFib treatment and add to real-world evidence of its safety and durability. The system, widely adopted globally, has received regulatory approvals in China, Australia, and Japan, enhancing AFib care across the Asia Pacific region.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Sep 30,2024

MCRA Supports CamDiab with FDA Approval for Artificial Pancreas Software

MCRA, a leading Clinical Research Organization (CRO), assisted CamDiab in securing FDA clearance for their artificial pancreas app, CamAPS FX. The app, designed for managing type 1 diabetes, uses a hybrid closed-loop system that connects a continuous glucose monitor and insulin pump to regulate glucose levels automatically. MCRA's expertise in digital health and quality assurance, along with an innovative pre-determined change control plan (PCCP), enabled smoother software updates. This FDA approval marks a major step forward in diabetes management technology, offering improved care for users, including pregnant women and young children.

REGULATORY FDA
View Analyst & Ambassador Comments
Go to original news
Jun 27,2024

Dexcom Schedules Second Quarter 2024 Earnings Release and Conference Call for July 25, 2024 at 4:30 p.m. Eastern Time.

DexCom, Inc. (NASDAQ:DXCM) announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 22,2024

Abbott Completes Acquisition of Bigfoot Biomedical

Abbott today announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes. The transaction expands Abbott’s presence in diabetes care, building on its world-leading FreeStyle Libre® portfolio of continuous glucose monitoring technology and furthering the company’s efforts to develop connected solutions for making diabetes management even more personal and precise.

View Analyst & Ambassador Comments
Go to original news
Sep 24,2024

Rimidi Increases Customer Base by 400%, Expands Partnerships and Services in 2024 to Support Future Growth

Rimidi, a leading digital health company, reported a 400% year-on-year growth in its customer base, now reaching over 150,000 patients. The company, known for its EHR-integrated software and services, supports healthcare providers in remote patient monitoring (RPM) and chronic disease management. This surge includes large health systems, clinics, and independent practices. In 2024, Rimidi launched the Rimidi Care Network to help providers scale RPM programs, while forming new partnerships with healthcare tech companies like Adherium, Senseonics, and Tenovi. Other milestones include a TX-RAMP cybersecurity certification and collaborations to enhance postpartum care.

View Analyst & Ambassador Comments
Go to original news
Sep 25,2024

Medtronic expands AiBLE™ spine surgery ecosystem with new technologies and Siemens Healthineers partnership

Medtronic, a global leader in healthcare technology, has announced the commercial launch of several new software, hardware, and imaging advancements at the North American Spine Society's 39th Annual Meeting. These innovations, part of the AiBLE™ smart ecosystem, aim to improve outcomes in spine and cranial surgeries. Key developments include the O-arm™ 4.3 software for enhanced imaging, the UNiD™ Adaptive Spine Intelligence platform with AI-powered MRI Vision, and the Mazor™ robotic system with advanced preoperative planning features. In addition, Medtronic revealed a partnership with Siemens Healthineers to integrate the Multitom Rax™ imaging system into the AiBLE™ ecosystem, further expanding access to advanced pre- and post-operative imaging for spinal care. This collaboration is expected to improve surgical precision and patient outcomes.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 25,2024

ABBOTT HOSTS CONFERENCE CALL FOR THIRD-QUARTER EARNINGS

Abbott will release its third-quarter 2024 financial results on Wednesday, October 16, before the market opens. Following the announcement, a live webcast of the earnings conference call will take place at 8 a.m. Central time (9 a.m. Eastern) and can be accessed through Abbott's Investor Relations website. An archived version of the call will be available later that same day.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES